The effect of Chinese herbal medicine on male factor infertility: study protocol for a randomized controlled trial

The Effect of Chinese Herbal Medicine on Male Factor Infertility: Study Protocol for a Randomized Controlled Trial

Background

The global prevalence of infertility is 9%, with male factors potentially accounting for 40% to 60% of cases. Conventional treatments can be ineffective, invasive, costly, and linked to adverse effects and high risks. Previous studies have shown that Chinese herbal medicine (CHM) can regulate the hypothalamus-pituitary-testis axis, improve sperm abnormalities and quality, mitigate oxidative stress, and decrease DNA fragmentation index (DFI). However, the evidence backing the use of CHM for treating male factor infertility lacks conviction due to study design limitations, and there remains a scarcity of studies on the live birth rate following CHM treatment for male factor infertility. Here, we describe the rationale and design of a randomized waitlist-controlled trial to evaluate the effect of CHM on the live birth rate among males with infertility.

Methods

This study is a single-center, randomized, waitlist-controlled study. A total of 250 couples diagnosed with male factor infertility will be enrolled in this study and then randomly allocated into two groups in a 1:1 ratio. Male participants in CHM group (treatment group) will receive CHM once a day for 3 months. Male participants in the waitlist group (control group) will not receive any treatment for 3 months. After 3 months, participants in both groups need to be followed up for another 12 months. The primary outcome will be the live birth rate; secondary outcomes include semen quality parameters, DFI, and pregnancy-related outcomes. Safety will also be assessed.

Discussion

The purpose of this trial is to explore the effects and safety of CHM on the live birth rate among couples dealing with male factor infertility. The outcome of this trial may provide a viable treatment option for male factor infertility.

Trial Registration

Chinese Clinical Trial Registry: ChiCTR2200064416. Registered on 7 October 2022, ChiCTR.

Value of Clinical Trials and Practical Solutions

Clinical trials are key to developing safe and effective treatments. It’s important to extend their benefits into everyday medical practice. DocSym, our AI-driven platform, helps by consolidating ICD-11 standards, clinical protocols, and research into a single, easily accessible knowledge base for clinicians.

Streamlining Healthcare Operations

In today’s healthcare environment, streamlining operations is crucial. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally.

Enhancing Workflows with AI

By using AI, clinics can enhance their workflows and improve patient outcomes, reducing paper routine. Learn more about how we can help at aidevmd.com.

AI Products for Business or Try Custom Development

AI Sales Bot

Welcome AI Sales Bot, your 24/7 teammate! Engaging customers in natural language across all channels and learning from your materials, it’s a step towards efficient, enriched customer interactions and sales

AI Document Assistant

Unlock insights and drive decisions with our AI Insights Suite. Indexing your documents and data, it provides smart, AI-driven decision support, enhancing your productivity and decision-making.

AI Customer Support

Upgrade your support with our AI Assistant, reducing response times and personalizing interactions by analyzing documents and past engagements. Boost your team and customer satisfaction

AI Scrum Bot

Enhance agile management with our AI Scrum Bot, it helps to organize retrospectives. It answers queries and boosts collaboration and efficiency in your scrum processes.